Literature DB >> 18553054

Specificity of the anti-glycolytic activity of 3-bromopyruvate confirmed by FDG uptake in a rat model of breast cancer.

Manon Buijs1, Josephina A Vossen, Jean-Francois H Geschwind, Takayoshi Ishimori, James M Engles, Obele Acha-Ngwodo, Richard L Wahl, Mustafa Vali.   

Abstract

PURPOSE: To evaluate the anti-glycolytic effects of 3-BrPA on rats bearing RMT mammary tumors, by determining FDG uptake after intravenous administration of the therapeutic dose.
MATERIALS AND METHODS: Sixteen rats bearing RMT tumors were treated either with 15 mM 3-BrPA in 2.5 ml of PBS or with 2.5 ml of PBS. After treatment, all rats received FDG and were sacrificed 1 h later.
RESULTS: 3-BrPA treatment significantly decreased FDG uptake in tumors by 77% (p = 0.002). FDG uptake did not significantly decrease in normal tissues after treatment.
CONCLUSION: Our study showed that 3-BrPA exhibits a strong anti-glycolytic effect on RMT cells implanted in rats.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18553054     DOI: 10.1007/s10637-008-9145-0

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  26 in total

Review 1.  Oncological applications of FDG PET imaging.

Authors:  D Delbeke
Journal:  J Nucl Med       Date:  1999-10       Impact factor: 10.057

Review 2.  Current management of metastatic breast cancer.

Authors:  E A Perez
Journal:  Semin Oncol       Date:  1999-08       Impact factor: 4.929

3.  Determination of 2-fluoro-2-deoxy-D-glucose uptake and ATP level for evaluating drug effects in neoplastic cells.

Authors:  H Minn; L Kangas; V Knuutila; R Paul; H Sipilä
Journal:  Res Exp Med (Berl)       Date:  1991

Review 4.  PET and PET/CT using 18F-FDG in the diagnosis and management of cancer patients.

Authors:  Keigo Endo; Noboru Oriuchi; Tetsuya Higuchi; Yasuhiko Iida; Hirofumi Hanaoka; Mitsuyuki Miyakubo; Tomohiro Ishikita; Keiko Koyama
Journal:  Int J Clin Oncol       Date:  2006-08       Impact factor: 3.402

5.  Serum glucose: effects on tumor and normal tissue accumulation of 2-[F-18]-fluoro-2-deoxy-D-glucose in rodents with mammary carcinoma.

Authors:  R L Wahl; C A Henry; S P Ethier
Journal:  Radiology       Date:  1992-06       Impact factor: 11.105

6.  Factors influencing [F-18] 2-fluoro-2-deoxy-D-glucose (F-18 FDG) uptake in melanoma cells: the role of proliferation rate, viability, glucose transporter expression and hexokinase activity.

Authors:  Kiyoshi Yamada; Ingo Brink; Emmanuel Bissé; Thomas Epting; Rupert Engelhardt
Journal:  J Dermatol       Date:  2005-05       Impact factor: 4.005

7.  Importance of extended growth potential and growth factor independence on in vivo neoplastic potential of primary rat mammary carcinoma cells.

Authors:  S P Ethier; K C Cundiff
Journal:  Cancer Res       Date:  1987-10-15       Impact factor: 12.701

8.  Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis.

Authors:  N Avril; M Menzel; J Dose; M Schelling; W Weber; F Jänicke; W Nathrath; M Schwaiger
Journal:  J Nucl Med       Date:  2001-01       Impact factor: 10.057

9.  Breast carcinomas fulfill the Warburg hypothesis and provide metabolic markers of cancer prognosis.

Authors:  Antonio Isidoro; Enrique Casado; Andrés Redondo; Paloma Acebo; Enrique Espinosa; Andrés M Alonso; Paloma Cejas; David Hardisson; Juan A Fresno Vara; Cristobal Belda-Iniesta; Manuel González-Barón; José M Cuezva
Journal:  Carcinogenesis       Date:  2005-07-20       Impact factor: 4.944

Review 10.  Evaluating distant metastases in breast cancer: from biology to outcomes.

Authors:  Shafaat A Rabbani; Andrew P Mazar
Journal:  Cancer Metastasis Rev       Date:  2007-12       Impact factor: 9.264

View more
  13 in total

1.  Changing the energy of an immune response.

Authors:  Meghan M Delmastro-Greenwood; Jon D Piganelli
Journal:  Am J Clin Exp Immunol       Date:  2013-02-27

Review 2.  The Warburg effect: molecular aspects and therapeutic possibilities.

Authors:  Hanh Ngo; Stephanie M Tortorella; Katherine Ververis; Tom C Karagiannis
Journal:  Mol Biol Rep       Date:  2015-04       Impact factor: 2.316

3.  Metabolic perturbation sensitizes human breast cancer to NK cell-mediated cytotoxicity by increasing the expression of MHC class I chain-related A/B.

Authors:  Dexue Fu; Jean-Francois Geschwind; Swathi Karthikeyan; Eliyahu Miller; Rani Kunjithapatham; Zhijun Wang; Shanmugasundaram Ganapathy-Kanniappan
Journal:  Oncoimmunology       Date:  2015-01-14       Impact factor: 8.110

Review 4.  3-Bromopyruvate: targets and outcomes.

Authors:  Maria C Shoshan
Journal:  J Bioenerg Biomembr       Date:  2012-02       Impact factor: 2.945

Review 5.  The anticancer agent 3-bromopyruvate: a simple but powerful molecule taken from the lab to the bedside.

Authors:  J Azevedo-Silva; O Queirós; F Baltazar; S Ułaszewski; A Goffeau; Y H Ko; P L Pedersen; A Preto; M Casal
Journal:  J Bioenerg Biomembr       Date:  2016-07-25       Impact factor: 2.945

Review 6.  Prospects on strategies for therapeutically targeting oncogenic regulatory factors by small-molecule agents.

Authors:  Chih-Chien Chou; Santosh B Salunke; Samuel K Kulp; Ching-Shih Chen
Journal:  J Cell Biochem       Date:  2014-04       Impact factor: 4.429

Review 7.  Safety and outcome of treatment of metastatic melanoma using 3-bromopyruvate: a concise literature review and case study.

Authors:  Salah Mohamed El Sayed; Walaa Gamal Mohamed; Minnat-Allah Hassan Seddik; Al-Shimaa Ahmed Ahmed; Asmaa Gamal Mahmoud; Wael Hassan Amer; Manal Mohamed Helmy Nabo; Ahmed Roshdi Hamed; Nagwa Sayed Ahmed; Ali Abdel-Rahman Abd-Allah
Journal:  Chin J Cancer       Date:  2014-03-14

Review 8.  Targeting Cancer Metabolism - Revisiting the Warburg Effects.

Authors:  Quangdon Tran; Hyunji Lee; Jisoo Park; Seon-Hwan Kim; Jongsun Park
Journal:  Toxicol Res       Date:  2016-07-30

9.  A comparative analysis of inhibitors of the glycolysis pathway in breast and ovarian cancer cell line models.

Authors:  Chrysi Xintaropoulou; Carol Ward; Alan Wise; Hugh Marston; Arran Turnbull; Simon P Langdon
Journal:  Oncotarget       Date:  2015-09-22

Review 10.  Cancer-generated lactic acid: a regulatory, immunosuppressive metabolite?

Authors:  Stephen Yiu Chuen Choi; Colin C Collins; Peter W Gout; Yuzhuo Wang
Journal:  J Pathol       Date:  2013-08       Impact factor: 7.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.